The correlation between fatty liver disease and chronic kidney disease

Po Chun Chen, Wei Yu Kao, Yuan Lung Cheng, Yuan Jen Wang, Ming Chih Hou, Jaw Ching Wu, Chien Wei Su

Research output: Contribution to journalArticle

Abstract

Background/purpose: The impact of non-alcoholic fatty liver disease (NAFLD) on the prevalence of chronic kidney disease (CKD) is not fully elucidated. We aimed to assess the correlation between NAFLD and CKD in a large population study. Methods: We included consecutive subjects who had received health check-up service at Taipei Veterans General Hospital from 2002 to 2009. NAFLD was diagnosed with abdominal ultrasound, and advanced liver fibrosis was determined with NAFLD fibrosis score (NAFLD-FS). CKD was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 . Results: Among the 29,797 subjects enrolled in this study, NAFLD and CKD were diagnosed in 44.5% and 20.2% of the population, respectively. Subjects with NAFLD had a higher proportion of CKD compared to those without NAFLD (24.1% vs. 17.1%, p < 0.001). However, NAFLD was not related to CKD with an odds ratio (OR) of 1.015 (95% confidence interval [CI] 0.954–1.081, p = 0.630) after multivariate analyses. Nevertheless, further analyses revealed that among patients with NAFLD, those with advanced fibrosis were more likely to have CKD after adjusting for confounding factors (OR 2.284, 95% CI 1.513–3.448, p < 0.001). Conclusion: NAFLD per se was not a risk factor for CKD, but NAFLD patients with advanced fibrosis faced a higher possibility of CKD. Hence, patients with NAFLD and advanced fibrosis should be screened for CKD and prompted to receive treatment if the diagnosis was made.

Original languageEnglish
JournalJournal of the Formosan Medical Association
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Fatty Liver
Chronic Renal Insufficiency
Liver Diseases
Fibrosis
Liver Cirrhosis
Non-alcoholic Fatty Liver Disease
Odds Ratio
Confidence Intervals
Veterans Hospitals
Glomerular Filtration Rate
General Hospitals
Population
Multivariate Analysis

Keywords

  • Kidney diseases
  • Liver fibrosis
  • Non-alcoholic fatty liver disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The correlation between fatty liver disease and chronic kidney disease. / Chen, Po Chun; Kao, Wei Yu; Cheng, Yuan Lung; Wang, Yuan Jen; Hou, Ming Chih; Wu, Jaw Ching; Su, Chien Wei.

In: Journal of the Formosan Medical Association, 01.01.2019.

Research output: Contribution to journalArticle

Chen, Po Chun ; Kao, Wei Yu ; Cheng, Yuan Lung ; Wang, Yuan Jen ; Hou, Ming Chih ; Wu, Jaw Ching ; Su, Chien Wei. / The correlation between fatty liver disease and chronic kidney disease. In: Journal of the Formosan Medical Association. 2019.
@article{58de12fa2fe640dc8dc034a16e97657d,
title = "The correlation between fatty liver disease and chronic kidney disease",
abstract = "Background/purpose: The impact of non-alcoholic fatty liver disease (NAFLD) on the prevalence of chronic kidney disease (CKD) is not fully elucidated. We aimed to assess the correlation between NAFLD and CKD in a large population study. Methods: We included consecutive subjects who had received health check-up service at Taipei Veterans General Hospital from 2002 to 2009. NAFLD was diagnosed with abdominal ultrasound, and advanced liver fibrosis was determined with NAFLD fibrosis score (NAFLD-FS). CKD was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 . Results: Among the 29,797 subjects enrolled in this study, NAFLD and CKD were diagnosed in 44.5{\%} and 20.2{\%} of the population, respectively. Subjects with NAFLD had a higher proportion of CKD compared to those without NAFLD (24.1{\%} vs. 17.1{\%}, p < 0.001). However, NAFLD was not related to CKD with an odds ratio (OR) of 1.015 (95{\%} confidence interval [CI] 0.954–1.081, p = 0.630) after multivariate analyses. Nevertheless, further analyses revealed that among patients with NAFLD, those with advanced fibrosis were more likely to have CKD after adjusting for confounding factors (OR 2.284, 95{\%} CI 1.513–3.448, p < 0.001). Conclusion: NAFLD per se was not a risk factor for CKD, but NAFLD patients with advanced fibrosis faced a higher possibility of CKD. Hence, patients with NAFLD and advanced fibrosis should be screened for CKD and prompted to receive treatment if the diagnosis was made.",
keywords = "Kidney diseases, Liver fibrosis, Non-alcoholic fatty liver disease",
author = "Chen, {Po Chun} and Kao, {Wei Yu} and Cheng, {Yuan Lung} and Wang, {Yuan Jen} and Hou, {Ming Chih} and Wu, {Jaw Ching} and Su, {Chien Wei}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jfma.2019.02.010",
language = "English",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",

}

TY - JOUR

T1 - The correlation between fatty liver disease and chronic kidney disease

AU - Chen, Po Chun

AU - Kao, Wei Yu

AU - Cheng, Yuan Lung

AU - Wang, Yuan Jen

AU - Hou, Ming Chih

AU - Wu, Jaw Ching

AU - Su, Chien Wei

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/purpose: The impact of non-alcoholic fatty liver disease (NAFLD) on the prevalence of chronic kidney disease (CKD) is not fully elucidated. We aimed to assess the correlation between NAFLD and CKD in a large population study. Methods: We included consecutive subjects who had received health check-up service at Taipei Veterans General Hospital from 2002 to 2009. NAFLD was diagnosed with abdominal ultrasound, and advanced liver fibrosis was determined with NAFLD fibrosis score (NAFLD-FS). CKD was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 . Results: Among the 29,797 subjects enrolled in this study, NAFLD and CKD were diagnosed in 44.5% and 20.2% of the population, respectively. Subjects with NAFLD had a higher proportion of CKD compared to those without NAFLD (24.1% vs. 17.1%, p < 0.001). However, NAFLD was not related to CKD with an odds ratio (OR) of 1.015 (95% confidence interval [CI] 0.954–1.081, p = 0.630) after multivariate analyses. Nevertheless, further analyses revealed that among patients with NAFLD, those with advanced fibrosis were more likely to have CKD after adjusting for confounding factors (OR 2.284, 95% CI 1.513–3.448, p < 0.001). Conclusion: NAFLD per se was not a risk factor for CKD, but NAFLD patients with advanced fibrosis faced a higher possibility of CKD. Hence, patients with NAFLD and advanced fibrosis should be screened for CKD and prompted to receive treatment if the diagnosis was made.

AB - Background/purpose: The impact of non-alcoholic fatty liver disease (NAFLD) on the prevalence of chronic kidney disease (CKD) is not fully elucidated. We aimed to assess the correlation between NAFLD and CKD in a large population study. Methods: We included consecutive subjects who had received health check-up service at Taipei Veterans General Hospital from 2002 to 2009. NAFLD was diagnosed with abdominal ultrasound, and advanced liver fibrosis was determined with NAFLD fibrosis score (NAFLD-FS). CKD was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 . Results: Among the 29,797 subjects enrolled in this study, NAFLD and CKD were diagnosed in 44.5% and 20.2% of the population, respectively. Subjects with NAFLD had a higher proportion of CKD compared to those without NAFLD (24.1% vs. 17.1%, p < 0.001). However, NAFLD was not related to CKD with an odds ratio (OR) of 1.015 (95% confidence interval [CI] 0.954–1.081, p = 0.630) after multivariate analyses. Nevertheless, further analyses revealed that among patients with NAFLD, those with advanced fibrosis were more likely to have CKD after adjusting for confounding factors (OR 2.284, 95% CI 1.513–3.448, p < 0.001). Conclusion: NAFLD per se was not a risk factor for CKD, but NAFLD patients with advanced fibrosis faced a higher possibility of CKD. Hence, patients with NAFLD and advanced fibrosis should be screened for CKD and prompted to receive treatment if the diagnosis was made.

KW - Kidney diseases

KW - Liver fibrosis

KW - Non-alcoholic fatty liver disease

UR - http://www.scopus.com/inward/record.url?scp=85062616136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062616136&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2019.02.010

DO - 10.1016/j.jfma.2019.02.010

M3 - Article

AN - SCOPUS:85062616136

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

ER -